List of Excipients in Branded Drug AMLODIPINE AND OLMESARTAN MEDOXOMIL

Generic Drugs Containing AMLODIPINE AND OLMESARTAN MEDOXOMIL

Company	Ingredient	NDC	Excipient
Torrent Pharmaceuticals Limited	amlodipine and olmesartan medoxomil	13668-324	CROSCARMELLOSE SODIUM
Torrent Pharmaceuticals Limited	amlodipine and olmesartan medoxomil	13668-324	LACTOSE MONOHYDRATE
Torrent Pharmaceuticals Limited	amlodipine and olmesartan medoxomil	13668-324	MAGNESIUM STEARATE
Torrent Pharmaceuticals Limited	amlodipine and olmesartan medoxomil	13668-324	POLYETHYLENE GLYCOL 400
Torrent Pharmaceuticals Limited	amlodipine and olmesartan medoxomil	13668-324	POLYVINYL ALCOHOL
Torrent Pharmaceuticals Limited	amlodipine and olmesartan medoxomil	13668-324	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in AMLODIPINE AND OLMESARTAN MEDOXOMIL?

# Of NDCs	Excipient
6	ANHYDROUS LACTOSE
18	CELLULOSE, MICROCRYSTALLINE
18	CROSCARMELLOSE SODIUM
1	CROSPOVIDONE
1	FD&C RED NO. 40
1	FD&C YELLOW NO. 6

Amlodipine and Olmesartan Medoxomil Excipient Strategy and Commercial Opportunities

Last updated: August 14, 2026

Amlodipine/olmesartan medoxomil is an immediate-release fixed-dose antihypertensive combination marketed in the United States as Azor. The product combines a dihydropyridine calcium-channel blocker with an angiotensin II receptor blocker. Its commercial opportunity is strongest in low-cost generic substitution, differentiated fixed-dose strengths, adherence-focused packaging, and selected alternate dosage forms.

The most defensible excipient strategy is a conventional, scalable immediate-release tablet using compendial fillers, disintegrants, glidants, lubricants, and colorants. The primary technical risks are dose uniformity across low-dose amlodipine strengths, olmesartan medoxomil stability, dissolution matching, excipient compatibility, and control of tablet size across multiple strength combinations.

What is the FDA-approved composition of amlodipine and olmesartan medoxomil?

The reference product is Azor, which contains amlodipine besylate and olmesartan medoxomil. FDA-approved strengths include:

Amlodipine component	Olmesartan medoxomil component	Approximate marketed strength
5 mg	20 mg	5/20 mg
5 mg	40 mg	5/40 mg
10 mg	20 mg	10/20 mg
10 mg	40 mg	10/40 mg

Azor was approved by the FDA in 2007 for hypertension in patients who are not adequately controlled on monotherapy or as initial therapy in selected patients likely to require multiple agents.[1]

The FDA label identifies inactive ingredients including microcrystalline cellulose, lactose monohydrate, low-substituted hydroxypropyl cellulose, colloidal silicon dioxide, magnesium stearate, and iron oxide colorants.[1] These excipients support a conventional compressed-tablet platform and are widely available from multiple suppliers.

What excipients are used in Azor tablets?

The key excipient classes are:

Excipient class	Representative excipient	Functional purpose
Diluent and compression aid	Microcrystalline cellulose	Tablet bulk, compactability, disintegration support
Water-soluble filler	Lactose monohydrate	Mass balance and palatability
Disintegrant	Low-substituted hydroxypropyl cellulose	Tablet breakup and drug release
Glidant	Colloidal silicon dioxide	Powder flow and blend uniformity
Lubricant	Magnesium stearate	Ejection and tooling protection
Colorant	Iron oxide	Product identification and strength differentiation

The reference excipient system has commercial advantages because it uses standard pharmaceutical-grade materials rather than specialized polymers, lipid systems, or proprietary delivery technologies. That lowers formulation cost, simplifies supplier qualification, and supports conventional high-speed tableting.

Why is microcrystalline cellulose commercially important?

Microcrystalline cellulose provides a robust compression platform for a combination product with unequal dose ratios. It can help compensate for the relatively small quantity of amlodipine in the 5 mg strength while maintaining tablet mass and mechanical strength.

A formulation developer should control:

• Particle-size distribution.
• Moisture content.
• Bulk and tapped density.
• Powder flow.
• Compactability under production-scale compression.
• Variability between supplier grades.

A change in microcrystalline cellulose grade can affect hardness, friability, disintegration, and dissolution. For an ANDA product, the applicant should assess whether the change remains within the product’s established critical material attributes and whether additional comparative dissolution or stability work is required.

What role does low-substituted hydroxypropyl cellulose play?

Low-substituted hydroxypropyl cellulose is used as a disintegrant and can also contribute to tablet structure. It is suitable for immediate-release products because it promotes water uptake and tablet breakup without creating the sustained-release barrier associated with high-viscosity polymers.

Its level should be optimized against:

• Disintegration time.
• Dissolution in discriminatory media.
• Tablet hardness.
• Friability.
• Blend uniformity.
• Sensitivity to compression force.

Excessive compression or insufficient disintegrant can delay dissolution, particularly for a combination tablet that must release both active ingredients promptly.

How should manufacturers design the excipient platform?

A commercially efficient platform should use a common core formula across all four strengths, with controlled changes in active-ingredient quantities and colorant where needed. The goal is to avoid separate manufacturing processes for each strength.

Direct compression versus wet granulation

Direct compression offers the lowest process complexity and the shortest manufacturing cycle. It is attractive when both active ingredients and excipients have adequate flow, compressibility, and blend uniformity.

Wet granulation may be preferable if the formulation shows:

• Poor flow of one active ingredient.
• Segregation caused by density differences.
• Low-dose amlodipine uniformity problems.
• High tablet-weight variability.
• Inadequate compactability.
• Dissolution sensitivity to lubricant distribution.

A high-shear or fluid-bed granulation process can improve content uniformity, but it adds water or solvent exposure, drying controls, process validation requirements, and potential stability risks. The selected process should be driven by blend uniformity and dissolution performance rather than by an assumption that the reference product uses a particular process.

Should the two active ingredients be granulated separately?

Separate processing can reduce segregation and improve control over the low-dose amlodipine component. It can also allow different particle-size or surface-treatment strategies for each active ingredient.

The disadvantages are higher manufacturing cost, more intermediate controls, increased batch complexity, and a greater risk of process-specific differences from the reference product. A shared granulation or direct-compression process is commercially preferable when it can meet content-uniformity and dissolution targets.

What are the main compatibility concerns?

Amlodipine besylate and olmesartan medoxomil should be evaluated with each proposed excipient under accelerated and long-term conditions. The study package should include:

• Binary active-excipient compatibility screening.
• Moisture-stress testing.
• Thermal analysis.
• Related-substance profiling.
• Photostability testing.
• Dissolution after storage.
• Packaging compatibility.

The formulation should minimize unnecessary moisture and reactive impurities. Lactose, cellulose derivatives, lubricants, and colorants should be assessed for their impact on degradation pathways and assay recovery. The commercial formulation should use tight supplier specifications for water content, peroxide or aldehyde impurities where relevant, and elemental impurities.

What formulation patents protect amlodipine and olmesartan medoxomil?

The original commercial combination was developed and marketed by Daiichi Sankyo and associated entities. The active pharmaceutical ingredient patents for amlodipine and olmesartan medoxomil were separate from the fixed-dose combination product and had different expiration histories.

The original U.S. composition-of-matter protection for olmesartan medoxomil expired years before the current generic market. Amlodipine also has long-established generic availability. Any remaining commercial protection for the combination is therefore more likely to depend on:

• Fixed-dose combination claims.
• Specific tablet compositions.
• Manufacturing processes.
• Method-of-use claims.
• Pediatric exclusivity or regulatory exclusivity.
• Non-U.S. national rights.
• Brand-specific trademarks and market access arrangements.

Patent status must be verified in the current FDA Orange Book, USPTO Patent Center, FDA patent-listing records, and relevant court dockets. A current freedom-to-operate opinion should not rely on historical Orange Book entries alone.

What is the Orange Book status of Azor?

Azor is an approved small-molecule combination product listed in the FDA Orange Book. Orange Book listings may include patents associated with the reference drug and may change through delisting, expiration, or regulatory updates.[2]

For an ANDA applicant, the relevant analysis is:

1. Identify all currently listed patents for the reference drug.
2. Confirm whether each patent claims the drug substance, drug product, or method of use.
3. Determine the applicable expiration date and any pediatric extension.
4. Select Paragraph I, II, III, or IV certifications as appropriate.
5. Assess whether a Paragraph IV notice could trigger 30-month litigation-based approval delay.

Historical patent expiration does not eliminate the need to review live listings, terminal disclaimers, patent reexaminations, settlements, or later-listed patents.

When does amlodipine/olmesartan lose exclusivity?

The combination has already entered the U.S. generic market. Loss of practical exclusivity occurred after the relevant regulatory and patent barriers expired or were addressed through ANDA approvals and litigation outcomes.

The market should be evaluated by three separate concepts:

Exclusivity type	Relevance
Regulatory exclusivity	Historical protection tied to the original NDA approval
Patent exclusivity	Claims covering the active ingredients, combination, formulation, or use
Commercial exclusivity	Brand share retained through prescribing, contracting, and channel access

The combination’s commercial lifecycle is mature. Future opportunities are therefore unlikely to depend on blocking generic competition. They depend on cost position, supply reliability, dosage-form differentiation, and market access.

Which companies are challenging or competing with Azor?

The competitive field includes:

• Authorized and independent generic manufacturers of amlodipine/olmesartan.
• Manufacturers of separate amlodipine and olmesartan tablets.
• Other fixed-dose angiotensin receptor blocker/calcium-channel blocker combinations.
• Single-tablet regimens containing amlodipine with valsartan, losartan, or telmisartan.
• Combination antihypertensive products that include a thiazide diuretic.

Generic competition is strongest where the product is reimbursed through pharmacy benefit managers, Medicaid programs, institutional tenders, and retail generic formularies. A product that combines both actives in one tablet can retain value despite low unit pricing because it reduces pill burden and may improve persistence.

What commercial opportunities exist for new excipient systems?

Low-cost generic immediate-release tablets

The largest opportunity is a bioequivalent tablet using standard excipients and a common manufacturing platform. Competitive advantages include:

• Lower tablet cost.
• Fewer process steps.
• Multiple approved strengths from one formulation family.
• Robust shelf life.
• Dual-source excipient procurement.
• Broad contract-manufacturing availability.

A simple formulation is preferable because the reference product does not require controlled release, intestinal targeting, taste masking, or a complex delivery device.

High-dose and low-dose strength optimization

The 5/20 mg strength presents the greatest risk of low-dose uniformity because the amlodipine component represents a small fraction of total tablet mass. A manufacturer can improve performance through:

• Pre-blending amlodipine with a portion of microcrystalline cellulose.
• Controlled particle-size distribution.
• Separate granulation of the amlodipine fraction.
• Geometric dilution.
• In-process blend sampling.
• Near-infrared or other process analytical technology.

A robust formulation that maintains content uniformity at commercial scale can reduce batch failures and improve supply reliability.

Alternate tablet appearance and packaging

Colorants and debossing can support strength differentiation and reduce medication errors. Packaging opportunities include:

• Calendar blister packs.
• 30-day adherence packs.
• Unit-dose hospital packaging.
• Child-resistant bottles.
• Moisture-protective high-barrier packaging.

Packaging differentiation is more commercially realistic than a new excipient technology for this product. It can support adherence and channel-specific contracts without creating major bioequivalence risk.

Orally disintegrating tablets

An orally disintegrating tablet could target patients with swallowing difficulty or adherence barriers. The technical challenge is that the product contains two active ingredients with different physical properties and must still meet immediate-release dissolution requirements.

Potential excipients include:

• Mannitol or other soluble fillers.
• Crospovidone or croscarmellose sodium.
• Low-moisture binders.
• Flavoring agents.
• Sweeteners.
• Silicon dioxide.
• Taste-masking polymers.

The opportunity is commercially differentiated but regulatory risk is higher. Taste, tablet friability, moisture sensitivity, packaging, and bioequivalence would require careful development. The product would also compete with low-cost standard tablets, limiting its price premium.

Sprinkle or dispersible formulations

A sprinkle formulation may address patients who cannot swallow conventional tablets. This route creates additional requirements for:

• Dose recovery from food or liquid.
• Stability after dispersion.
• Uniformity after mixing.
• Food-effect assessment.
• Labeling of administration instructions.
• Palatability.

It is a niche opportunity rather than a broad replacement for the conventional tablet.

Pediatric formulation

Pediatric use is constrained by the approved labeling, clinical dosing requirements, tablet strength, taste, and the need for age-appropriate administration. A liquid formulation could use suspending agents, wetting agents, buffers, preservatives, and taste-masking systems, but it would introduce microbial, sedimentation, redispersibility, and stability risks.

A pediatric product would require a clear regulatory and clinical strategy. It should not be treated as a simple reformulation opportunity.

What FDA regulatory pathway applies to a generic product?

A conventional generic would generally be submitted through an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant would need to demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug.[3]

The development package typically includes:

• Same active ingredients.
• Same dosage form and route.
• Equivalent strength.
• Comparable labeling, subject to permitted differences.
• Pharmaceutical equivalence.
• In vitro dissolution.
• In vivo bioequivalence when required.
• Stability data.
• Manufacturing controls.
• Impurity and elemental-impurity assessments.

A new dosage form, modified release, or clinically differentiated formulation may require a 505(b)(2) application instead of an ANDA. That pathway can support product differentiation but usually requires a more extensive regulatory and clinical justification.

What generic entry risks exist for amlodipine/olmesartan?

The main entry risks are operational and regulatory rather than fundamental patent barriers.

Risk	Commercial effect	Mitigation
Amlodipine blend segregation	Content-uniformity failure	Ordered blending, granulation, PAT
Dissolution mismatch	ANDA deficiency or bioequivalence risk	Comparative dissolution across media
Excipient variability	Batch-to-batch performance changes	Qualified suppliers and material controls
Moisture-related degradation	Shelf-life reduction	High-barrier packaging and low-moisture processing
Tablet size	Poor patient acceptance	Common-core formulation and mass optimization
Supply interruption	Lost tenders and wholesaler access	Dual sourcing and safety stock
Price erosion	Low margins	High-throughput manufacturing and limited SKU complexity
Labeling differences	Regulatory review delay	Reference-label mapping

Nitrosamine and other mutagenic-impurity controls should be incorporated into supplier qualification and lifecycle management. Regulatory expectations apply to the finished product, active ingredients, excipients, and manufacturing process where relevant.[4]

How does amlodipine/olmesartan compare with competing fixed-dose combinations?

Product class	Commercial strength	Excipient and formulation implication
Amlodipine/olmesartan	Two-drug regimen with established use	Conventional immediate-release tablet is sufficient
Amlodipine/valsartan	Broad hypertension familiarity	Competes directly for ARB/calcium-channel-blocker prescriptions
Amlodipine/telmisartan	Strong once-daily positioning	May compete where longer half-life or formulary preference matters
Amlodipine/losartan	Generic, low-cost alternative	Greater price pressure
ARB/CCB/thiazide combinations	Higher pill-burden reduction	More complex formulation and broader hypertension coverage

The principal commercial advantage of amlodipine/olmesartan is the established fixed-dose combination, not a unique excipient technology. Its main disadvantages are generic price erosion and competition from other ARB/calcium-channel-blocker combinations.

What is the revenue exposure and commercial outlook?

Azor revenue exposure is limited by generic competition and the maturity of the antihypertensive market. A new entrant should model revenue through volume rather than premium pricing.

The most relevant commercial drivers are:

• Pharmacy benefit manager formulary placement.
• Medicaid and Medicare reimbursement.
• Wholesaler and retail distribution.
• Number of approved strengths.
• Backorder performance.
• Manufacturing cost per tablet.
• Contracting strategy.
• Ability to supply both bottle and blister formats.
• Product availability during competitor shortages.

A standard generic may have limited margin but predictable demand. A differentiated product could command a higher price only if it solves a measurable problem, such as swallowing difficulty, adherence, packaging, or supply continuity.

Key Takeaways

• Amlodipine/olmesartan medoxomil is a mature immediate-release fixed-dose combination marketed as Azor.
• The reference product uses conventional excipients, including microcrystalline cellulose, lactose monohydrate, low-substituted hydroxypropyl cellulose, colloidal silicon dioxide, magnesium stearate, and iron oxide colorants.
• The strongest generic strategy is a scalable common-core tablet formulation across the 5/20, 5/40, 10/20, and 10/40 mg strengths.
• Low-dose amlodipine uniformity, dissolution, moisture control, and supplier variability are the principal formulation risks.
• Standard tablets offer the best cost and regulatory profile. Orally disintegrating, sprinkle, liquid, and pediatric products offer differentiation but carry greater development risk.
• U.S. entry generally proceeds through an ANDA, subject to current Orange Book patent listings and applicable certification requirements.
• Commercial success depends more on cost, supply reliability, contracting, and packaging than on proprietary excipient technology.

FAQs

Can lactose be replaced in an amlodipine/olmesartan tablet?

Yes. Lactose may be replaced with alternatives such as mannitol, dibasic calcium phosphate, or additional microcrystalline cellulose, but the change can affect compression, disintegration, dissolution, stability, and bioequivalence.

Is a bilayer tablet commercially justified for amlodipine/olmesartan?

Usually not for a conventional generic. A bilayer design may improve segregation control or enable separate release profiles, but it increases equipment, validation, and manufacturing costs without a clear therapeutic need.

Does olmesartan medoxomil require a solubility-enhancing excipient system?

A conventional immediate-release formulation can be adequate. Solubility-enhancing systems should be considered only if comparative dissolution or bioequivalence work identifies a performance limitation.

Can a new amlodipine/olmesartan formulation qualify for 505(b)(2) approval?

Potentially, if it introduces a meaningful change such as a new dosage form, route, release profile, or administration method and relies partly on the FDA’s findings for the reference product. The regulatory burden will exceed that of a standard ANDA.

Is there biosimilar risk for amlodipine/olmesartan?

No. Amlodipine and olmesartan medoxomil are small-molecule drugs, not biologics. The relevant competitive risks are generic ANDA entry, authorized generics, alternate fixed-dose combinations, and therapeutic substitution.

References

1. U.S. Food and Drug Administration. (2023). Azor (amlodipine besylate and olmesartan medoxomil) prescribing information. Daiichi Sankyo, Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda

3. U.S. Food and Drug Administration. (2024). ANDAs for certain highly purified synthetic peptides: Guidance for industry. https://www.fda.gov/drugs

4. U.S. Food and Drug Administration. (2023). Control of nitrosamine impurities in human drugs: Guidance for industry. https://www.fda.gov/drugs/drug-safety-and-availability